Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions

Oesophageal AdenocarcinomaTumor Microenvironment

Interventions

DRUG

Metformin

Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.

Trial Locations (2)

NOT_YET_RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

Amsterdam UMC, Amsterdam

All Listed Sponsors

collaborator

Cancer Center Amsterdam Research Foundation

UNKNOWN

lead

Amsterdam UMC, location VUmc

OTHER